Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon

Antiviral Therapy

Volumn 15, Issue 7, 2010, Pages 1039-1043

  Cournil, Amandine ^a   Coudray, Mathilde ^a   Kouanfack, Charles ^b   Essomba, Claudine Ntsama ^b   Tonfack, Clément Auguste Djouatsa ^b   Biwolé Sida, Magloire ^c   Delaporte, Eric ^a   Bork, Kirsten ^a   Laurent, Christian ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

^c MINISTRY OF PUBLIC HEALTH   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; STAVUDINE;

ADULT; ARTICLE; CAMEROON; CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CROSS-SECTIONAL STUDY; DRUG DOSE REDUCTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; CAMEROON; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; LIPODYSTROPHY; MALE; MIDDLE AGED; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

EID: 78651107916     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1664     Document Type: Article

References (21)

1. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364:29-34.
2. Makinson A, Moing VL, Kouanfack C, Laurent C, Delaporte E. Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings. Expert Opin Drug Saf 2008; 7:283-293. (Pubitemid 351802828)
3. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization 2006. (Updated 3 February 2009. Accessed 26 November 2009.) Available from http://www.who.int/hiv/pub/guidelines/artadultguidelines. pdf
4. World Health Organization. Important: addendum to the 2006 WHO guidelines on antiretroviral therapy for HIV infection in adults and adolescents: new dosage recommendations for stavudine (d4T). Geneva: World Health Organization 2007. (Updated 4 May 2007. Accessed 26 November 2009.) Available from http://www.who.int/hiv/art/ARTadultsaddendum.pdf
5. Ait-Mohand H, Bonmarchand M, Guiguet M, et al. Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study. HIV Med 2008;9:738-746.
6. McComsey GA, Lo Re V, III, O'Riordan M, et al. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis 2008; 46:1290-1296.
7. Milinkovic A, Martinez E, Lopez S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007;12:407-415.
8. Sanchez-Conde M, de Mendoza C, Jimenez-Nacher I, Barreiro P, Gonzalez-Lahoz J, Soriano V. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials 2005; 6:197-202. (Pubitemid 41601131)
9. Brinkman K. Stavudine in antiretroviral therapy: is this the end? AIDS 2009; 23:1727-1729.
10. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva: World Health Organization 2009. (Updated 23 February 2010. Accessed 11 March 2010.) Available from http://www.who.int/hiv/pub/arv/rapid-advice-art.pdf
11. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735. (Pubitemid 36293626)
12. Mercier S, Gueye NF, Cournil A, et al. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. J Acquir Immune Defic Syndr 2009; 51:224-230.
13. Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 46:451-455.
14. van Griensven J, De Naeyer L, Mushi T, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 2007; 101:793-798.
15. Zannou DM, Denoeud L, Lacombe K, et al. Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin. Antivir Ther 2009; 14:371-380.
16. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288:207-215. (Pubitemid 34755281)
17. McComsey GA, Paulsen DM, Lonergan JT, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19:15-23.
18. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33:22-28.
19. van Griensven J, Zachariah R, Rasschaert F, Atte EF, Reid T. Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir. Trans R Soc Trop Med Hyg 2009; 103:613-619.
20. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002; 31:50-55.
21. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592-598.